Latest Information Update: 08 Feb 2008
At a glance
- Originator AstraZeneca
- Class Bronchodilators
- Mechanism of Action 5-lipoxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 08 Feb 2008 Discontinued - Preclinical for Chronic obstructive pulmonary disease in United Kingdom (unspecified route)
- 27 Jan 2000 Preclinical development for Chronic obstructive pulmonary disease in United Kingdom (unspecified route)